Crinetics Pharmaceuticals, Inc. - Common Stock (CRNX)

Crinetics shares PATHFNDR trial data showing oral Palsonify maintained hormone and symptom control in acromegaly patients over 84–96 weeks.

The company presented new data at ENDO 2025 showing that patients who switched from monthly injections to the daily pill maintained hormone control and saw fewer symptom flare-ups over nearly two years.

JP Morgan's survey of endocrinologists finds strong awareness of Crinetics' atumelnant, with positive efficacy impressions. Analysts see long-term potential.

Stifel initiates coverage on CRNX, a clinical-stage pharmaceutical company focused on endocrine diseases and tumors.

Neurocrine's Crenessity receives FDA approval as a groundbreaking adjunctive treatment for classic CAH, offering a novel approach to hormone regulation.

CRNX stock results show that Crinetics Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.

10 mid-cap stocks jumped in last week, including QuantumScape, Lantheus Holdings, Sunrun, Kymera Therapeutics, Apogee Therapeutics, Joby Aviation, Crinetics Pharmaceuticals, Dyne Therapeutics, Summit Therapeutics, Plug Power and XPeng Inc.

With biotech stocks commanding a permanently relevant narrative, you can’t afford to ignore these highly endorsed ideas.

CRNX stock results show that Crinetics Pharmaceuticals missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.

Crinetics Pharmaceuticals unveils PATHFNDR-2 Phase 3 results for paltusotine in acromegaly treatment. Statistically significant efficacy & safety, with plans for FDA submission in 2024.

Shares of Peraso Inc. (NASDAQ: PRSO) fell sharply during Tuesday’s session after the company reported worse-than-expected fourth-quarter EPS results.

U.S. stocks were mixed, with the Dow Jones index gaining around 75 points on Tuesday.